Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity

• Published in: Rheumatology (Oxford, England) Vol. 57; no. 5; pp. 921 - 930
• Main Authors: Bodewes, Iris L A, Al-Ali, Shereen, van Helden-Meeuwsen, Cornelia G, Maria, Naomi I, Tarn, Jessica, Lendrem, Dennis W, Schreurs, Marco W J, Steenwijk, Eline C, van Daele, Paul L A, Both, Tim, Bowman, Simon J, Griffiths, Bridget, Ng, Wan-Fai, Versnel, Marjan A
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.05.2018; Oxford Publishing Limited (England)
• Subjects: Adult; Clinical trials; Female; Gene Expression Regulation; Humans; Immunoglobulin G; Interferon; Interferon Type I - biosynthesis; Interferon Type I - genetics; Interferon-gamma - biosynthesis; Interferon-gamma - genetics; Male; Middle Aged; Patients; Polymerase chain reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleic acid; RNA; RNA - genetics; Severity of Illness Index; Sjogren's syndrome; Sjogren's Syndrome - diagnosis; Sjogren's Syndrome - genetics; Sjogren's Syndrome - metabolism; interferon type II; fatigue; Sjögren's syndrome; interferon type I
• DOI: 10.1093/rheumatology/kex490
• ISSN: 1462-0324; 1462-0332

Abstract Objective To assess the relationships between systemic IFN type I (IFN-I) and II (IFN-II) activity and disease manifestations in primary SS (pSS). Methods RT-PCR of multiple IFN-induced genes followed by principal component analysis of whole blood RNA of 50 pSS patients was used to identify indicator genes of systemic IFN-I and IFN-II activities. Systemic IFN activation levels were analysed in two independent European cohorts (n = 86 and 55, respectively) and their relationships with clinical features were analysed. Results Three groups could be stratified according to systemic IFN activity: IFN inactive (19-47%), IFN-I (53-81%) and IFN-I + II (35-55%). No patient had isolated IFN-II activation. IgG levels were highest in patients with IFN-I + II, followed by IFN-I and IFN inactive patients. The prevalence of anti-SSA and anti-SSB was higher among those with IFN activation. There was no difference in total-EULAR SS Disease Activity Index (ESSDAI) or ClinESSDAI between the three subject groups. For individual ESSDAI domains, only the biological domain scores differed between the three groups (higher among the IFN active groups). For patient reported outcomes, there were no differences in EULAR Sjögren's syndrome patient reported index (ESSPRI), fatigue or dryness between groups, but pain scores were lower in the IFN active groups. Systemic IFN-I but not IFN-I + II activity appeared to be relatively stable over time. Conclusions Systemic IFN activation is associated with higher activity only in the ESSDAI biological domain but not in other domains or the total score. Our data raise the possibility that the ESSDAI biological domain score may be a more sensitive endpoint for trials targeting either IFN pathway.